Huai An Chen

Mr. Huai An Chen

Taipei Medical University, Taipei, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Chemical Engineering Journal
Verified
Journal Article
Closed access
YLYu-Jen Lu
Yu-Jen Lu
Er-Yuan ChuangEr-Yuan Chuang
Er-Yuan Chuang
YCYu-Hsin Cheng
Yu-Hsin Cheng
Anilkumar Thaghalli ShivannaAnilkumar Thaghalli Shivanna
Anilkumar Thaghalli Shivanna
HCHuai An Chen
Huai An Chen
Jyh-Ping ChenJyh-Ping Chen
Jyh-Ping Chen

Verified
Journal Article
Open access
PDF file
HCHuai An Chen
Huai An Chen
YMYunn-Hwa Ma
Yunn-Hwa Ma
THTzu-Yuan Hsu
Tzu-Yuan Hsu
Jyh-Ping ChenJyh-Ping Chen
Jyh-Ping Chen
Recombinant tissue plasminogen activator (rtPA) is the only thrombolytic agent that has been approved by the FDA for treatment of ischemic stroke. However, a high dose intravenous infusion is required to maintain effective drug concentration, owing to the short half-life of the thrombolytic drug, whereas a momentous limitation is the risk of bleeding. We envision a dual targeted strategy for rtPA delivery will be feasible to minimize the required dose of rtPA for treatment. For this purpose, rtPA and fibrin-avid peptide were co-immobilized to poly(lactic-co-glycolic acid) (PLGA) magnetic nanoparticles (PMNP) to prepare peptide/rtPA conjugated PMNPs (pPMNP-rtPA). During preparation, PMNP was first surface modified with avidin, which could interact with biotin. This is followed by binding PMNP-avidin with biotin-PEG-rtPA (or biotin-PEG-peptide), which was prepared beforehand by binding rtPA (or peptide) to biotin-PEG-maleimide while using click chemistry between maleimide and the single –SH group in rtPA (or peptide). The physicochemical property characterization indicated the successful preparation of the magnetic nanoparticles with full retention of rtPA fibrinolysis activity, while biological response studies underlined the high biocompatibility of all magnetic nanoparticles from cytotoxicity and hemolysis assays in vitro. The magnetic guidance and fibrin binding effects were also confirmed, which led to a higher thrombolysis rate in vitro using PMNP-rtPA or pPMNP-rtPA when compared to free rtPA after static or dynamic incubation with blood clots. Using pressure-dependent clot lysis model in a flow system, dual targeted pPMNP-rtPA could reduce the clot lysis time for reperfusion by 40% when compared to free rtPA at the same drug dosage. From in vivo targeted thrombolysis in a rat embolic model, pPMNP-rtPA was used at 20% of free rtPA dosage to restore the iliac blood flow in vascular thrombus that was created by injecting a blood clot to the hind limb area.

1 September 2021 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
BDBanendu Sunder Dash
Banendu Sunder Dash
YLYu-Jen Lu
Yu-Jen Lu
HCHuai An Chen
Huai An Chen
CCChi-Cheng Chuang
Chi-Cheng Chuang
Jyh-Ping ChenJyh-Ping Chen
Jyh-Ping Chen

24 February 2025 in Biomaterials
Verified
Journal Article
Open access
GLGuei-Sheung Liu
Guei-Sheung Liu
HCHuai An Chen
Huai An Chen
CCChe-Yi Chang
Che-Yi Chang
YCYin-Ju Chen
Yin-Ju Chen
YWYu-Yi Wu
Yu-Yi Wu
CTChingli Tseng
Chingli Tseng
Platelet-derived extracellular vesicles (PEVs) have drawn attention due to their multifunctionality, ease of procurement, and abundant supply from clinical-grade platelet concentrates. PEVs can be readily endocytosed due to their lipid bilayer membrane and nanoscale structure, enhancing the bioavailability and efficacy of their therapeutic effects. PEVs also contain various trophic factors that enhance their effectiveness as therapeutic agents. Given that nanomedicine provides benefits over traditional treatments for eye diseases by surpassing physical ocular barriers, PEVs combined with the anti-angiogenic agent, kaempferol (KM), were assessed for their capacity to inhibit abnormal blood vessel formation in the cornea. Characterization of the nanoparticles suggested the successful preparation of KM-loaded PEVs (PEV-KM) with a mean diameter of approximately 160 nm and an encapsulation efficiency of around 61 %. PEV-KM was effectively internalized into human vascular endothelial cells, resulting in inhibited function, as evidenced by lower wound closure rates, decreased tube formation capacity, and downregulation of angiogenesis-related gene expression. Moreover, prolonged ocular retention was observed following the topical application of PEV and PEV-KM in mouse eyes. In an alkali-burned corneal neovascularization (CoNV) mouse model, PEV (1 %) was found to decrease vessel formation in the injured cornea. However, the combination of PEV and KM (1 % PEV with KM 6 μg/mL) showed an even stronger effect in inhibiting CoNV and decreasing the expression of proangiogenic and inflammatory cytokines. Overall, our data suggests that the topical administration of PEVs, either alone or alongside KM (PEV-KM), is a promising therapy for the management of CoNV.

14 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HCHuai An Chen
Huai An Chen
YLYu Jen Lu
Yu Jen Lu
Banendu Sunder DashBanendu Sunder Dash
Banendu Sunder Dash
YCYin Kai Chao
Yin Kai Chao
Jyh-Ping ChenJyh-Ping Chen
Jyh-Ping Chen
Combination chemo-photothermal therapy with nanomaterials can reduce the dose of chemotherapeutic drugs required for effective cancer treatment by minimizing toxic side effects while improving survival times. Toward this end, we prepare hyaluronic acid (HA)-modified poly(lactic-co-glycolic acid) (PLGA) magnetic nanoparticles (MNP) for the CD44 receptor-mediated and magnetic field-guided dual-targeted delivery of cisplatin (CDDP). By co-encapsulating the CDDP and oleic acid-coated iron oxide MNP (IOMNP) in PLGA, the PMNPc was first prepared in a single emulsification/solvent evaporation step and successively surface modified with chitosan and HA to prepare the HA/PMNPc. Spherical HA/PMNPc nanoparticles of ~300 nm diameter can be prepared with 18 and 10% (w/w) loading content of CDDP and IOMNP and a pH-sensitive drug release to facilitate the endosomal release of the CDDP after intracellular uptake. This leads to the higher cytotoxicity of the HA/PMNPc toward the U87 glioblastoma cells than free CDDP with reduced IC50, a higher cell apoptosis rate, and the enhanced expression of cell apoptosis marker proteins. Furthermore, the nanoparticles show the hyperthermia effect toward U87 after short-term near-infrared (NIR) light exposure, which can further elevate the cell apoptosis/necrosis rate and upregulate the HSP70 protein expression due to the photothermal effects. The combined cancer therapeutic efficacy was studied in vivo using subcutaneously implanted U87 cells in nude mice. By using dual-targeted chemo-photothermal combination cancer therapy, the intravenously injected HA/PMNPc under magnetic field guidance and followed by NIR laser irradiation was demonstrated to be the most effective treatment modality by inhibiting the tumor growth and prolonging the survival time of the tumor-bearing nude mice.

1 March 2019 in Journal of Magnetism and Magnetic Materials
Verified
Journal Article
Closed access
GJGils Jose
Gils Jose
YLYu-Jen Lu
Yu-Jen Lu
HCHuai An Chen
Huai An Chen
HHHao-Lung Hsu
Hao-Lung Hsu
JHJung-Tung Hung
Jung-Tung Hung
Jyh-Ping ChenJyh-Ping Chen
Jyh-Ping Chen